<DOC>
	<DOCNO>NCT01529632</DOCNO>
	<brief_summary>The study assess safety efficacy fix combination product QVA149 versus component product QAB149 NVA237 , administer concurrently , patient moderate severe chronic obstructive pulmonary disease ( COPD ) .</brief_summary>
	<brief_title>Comparison Safety Efficacy Combination Product QVA149A Against Concurrent Administration Individual Components , QAB149 NVA237 , Patients With Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description>The study assess safety efficacy fix combination product QVA149 versus component product QAB149 NVA237 , administer concurrently , patient moderate severe chronic obstructive pulmonary disease ( COPD ) .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<criteria>Male female adult age ≥ 40 yrs Smoking history least 10 pack year Diagnosis COPD ( moderate severe classify Global Initiative Chronic Obstructive Lung Disease ( GOLD ) Guidelines , 2010 ) Postbronchodilator FEV1 &lt; 80 % ≥ 30 % predict normal value postbronchodilator FEV1/FVC ( force vital capacity ) &lt; 70 % Patients respiratory tract infection within 4 week prior Visit 1 Patients concomitant pulmonary disease Patients history asthma Any patient lung cancer history lung cancer Patients history certain cardiovascular comorbid condition Patients known history diagnosis alpha1 antitrypsin deficiency Patients active phase supervise pulmonary rehabilitation program Patients contraindicate inhaled anticholinergic agent β2 agonists Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>chronic obstructive pulmonary disease</keyword>
	<keyword>COPD</keyword>
	<keyword>QVA149</keyword>
	<keyword>QAB149</keyword>
	<keyword>NVA237</keyword>
	<keyword>indacaterol</keyword>
	<keyword>glycopyrronium bromide</keyword>
</DOC>